[11C]Methylated LY2181308
- PMID: 21542556
- Bookshelf ID: NBK54203
[11C]Methylated LY2181308
Excerpt
Survivin is a small protein (142 amino acids, 16.5 kDa) that belongs to the inhibitor of apoptosis protein (IAP) family (1). IAPs can effectively suppress apoptosis induced by a variety of stimuli, including death receptor activation, growth factor withdrawal, ionizing radiation, viral infection, and genotoxic damage. Survivin comprises a single baculovirus IAP repeat domain and an extended COOH-terminal α-helical coiled-coil domain but lacks the RING-finger domain found in other IAPs. In addition to suppressing apoptosis, survivin is involved in many essential cellular functions, such as cell division, cell stress response, and surveillance checkpoints. Survivin is strongly expressed in the majority of human tumor types (2). As a new target in cancer treatment, inhibition of survivin expression can be carried out through the use of anti-sense oligonucleotides, ribozymes, and small interfering RNA (3). LY2181308 is an 18-mer survivin anti-sense oligonucleotide (6.8 kDa) against survivin mRNA (4, 5). Dence et al. (6) developed a rapid method for randomly 11C-methylated LY2181308 ([11C]LY2181308) for positron emission tomography (PET) imaging of survivin mRNA expression in tumors.
Sections
Similar articles
-
Survivin specified small interfering RNA-CLIO-Cy5.5.2008 Apr 17 [updated 2008 May 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2008 Apr 17 [updated 2008 May 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641619 Free Books & Documents. Review.
-
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.Theranostics. 2011;1:290-301. doi: 10.7150/thno/v01p0290. Epub 2011 Jun 1. Theranostics. 2011. PMID: 21772926 Free PMC article.
-
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.Clin Cancer Res. 2010 Dec 15;16(24):6150-8. doi: 10.1158/1078-0432.CCR-10-1932. Epub 2010 Nov 1. Clin Cancer Res. 2010. PMID: 21041181
-
Survivin as a cell cycle-related and antiapoptotic protein in granulosa cells.Endocrinology. 2002 Sep;143(9):3405-13. doi: 10.1210/en.2002-220107. Endocrinology. 2002. PMID: 12193553
-
Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.Curr Mol Med. 2011 Nov;11(8):633-49. doi: 10.2174/156652411797536723. Curr Mol Med. 2011. PMID: 21902653 Review.
References
-
- Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. . Expert Opin Ther Targets. 2008;12(4):463–76. - PubMed
-
- Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. . Cancer Treat Rev. 2009;35(7):553–62. - PubMed
-
- Carrasco, R.A., N.B. Stamm, E.G. Marcusson, G.E. Sandusky, P. Iversen, and B.K. Patel, Antisense Inhibition of Survivin Expression as a Cancer Therapeutic. Mol Cancer Ther, 2011 - PubMed
-
- Rodel F., Frey B., Leitmann W., Capalbo G., Weiss C., Rodel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. . Int J Radiat Oncol Biol Phys. 2008;71(1):247–55. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous